iLite CDC Bioassays
Accurate Assessment of Antibody-Mediated Complement-Dependent Cytotoxicity
Accurate Assessment of Antibody-Mediated CDC
CDC Bioassays
Based on Svar’s proprietary iLite® technology, our Complement-Dependent Cytotoxicity (CDC) Bioassays offer a powerful tool for accurately measuring cell lysis in therapeutic antibody development.
iLite CDC Reporter Gene Assays
Our iLite assays streamline the assessment of antibody-mediated CDC, a crucial mechanism in immune responses and a common mechanism of action (MoA) for therapeutic antibodies.
- A true measure of cell lysis, ideal for screening mAbs with CDC MoA
- Uses the brilliant Svar LUC reporter-gene system for enhanced stability and precise quantification of cell death
- "Assay-ready" format for rapid and convenient use
- Easily adapted to other targets such as HER2, EGFR, mTNF, mVEGF, or your target of choice
Our CDC Reporter-Gene Assays
iLite® CD20 (+) Svar Luc Assay Ready Cells
Designed for sensitive and reproducible assessment of CDC activity
Didn't find what you were looking for?
We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.
iLite News
6 AUGUST 2025
Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Get...
Read post
10 JULY 2025
Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therap...
Read post
2 JULY 2025
Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection
Read post
30 JUNE 2025
AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement
Read post20+
years of product development
All 3
complement pathways studied individually
<5h
assay time
265+
scientific paper references
Contact our iLite team
Write us a message and a complement specialist will get in touch